STOCK TITAN
  1. Home
  2. Sec-filings
  3. ATXS
  4. [EFFECT] Astria Therapeutics, Inc. SEC Filing

[EFFECT] Astria Therapeutics, Inc. SEC Filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
EFFECT

Rhea-AI Filing Summary

Analyzing...
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date: January 27, 2026
Accession Number: 0001140361-26-002207
Submission Type: POS AM
CIK: 0001454789
Company Name: Astria Therapeutics, Inc.
File Number: 333-271848

Source: View Original Filing on SEC EDGAR

Astria Therapeutics Inc

NASDAQ:ATXS

View ATXS Stock Overview →

ATXS Rankings

#3105 Ranked by Market Cap
N/A Ranked by Dividends

ATXS Latest News

Jan 21, 2026
Astria Stockholders Vote to Approve Acquisition by BioCryst
Nov 12, 2025
Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
Nov 10, 2025
Intel Appoints Dr. Craig H. Barratt to Board of Directors
Nov 6, 2025
Astria Therapeutics Announces Final Positive Results from All Enrolled HAE Patients in the ALPHA-STAR Phase 1b/2 Trial of Navenibart
Oct 31, 2025
Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting

ATXS Latest SEC Filings

Feb 17, 2026
[SCHEDULE 13G/A] Astria Therapeutics, Inc. Amended Passive Investment Disclosure
Feb 12, 2026
[SCHEDULE 13G/A] Astria Therapeutics, Inc. Amended Passive Investment Disclosure
Feb 9, 2026
[SCHEDULE 13D/A] Astria Therapeutics, Inc. Amended Major Shareholder Report
Feb 2, 2026
[15-12G] Astria Therapeutics, Inc. SEC Filing
Jan 28, 2026
[SCHEDULE 13D/A] Astria Therapeutics, Inc. Amended Major Shareholder Report

ATXS Stock Data

718.13M
50.32M
Biotechnology
Pharmaceutical Preparations
Link
United States
BOSTON